EUR 2.85
(-2.9%)
Year | Total Debt | Total Debt Growth |
---|---|---|
2023 | 72.53 Million CAD | 3.79% |
2022 | 69.88 Million CAD | 26.08% |
2021 | 55.42 Million CAD | 18.02% |
2020 | 46.96 Million CAD | 95.57% |
2019 | 24.01 Million CAD | 40182.48% |
2018 | 59.61 Thousand CAD | -91.03% |
2017 | 664.67 Thousand CAD | -96.53% |
2016 | 19.16 Million CAD | 0.0% |
Year | Total Debt | Total Debt Growth |
---|---|---|
2024 Q2 | 67.62 Million CAD | 3.55% |
2024 Q1 | 65.31 Million CAD | -0.01% |
2024 Q3 | 66.42 Million CAD | -1.78% |
2023 Q3 | 63.1 Million CAD | -10.23% |
2023 Q1 | 68.4 Million CAD | -2.12% |
2023 Q2 | 70.29 Million CAD | 2.76% |
2023 FY | 72.53 Million CAD | 3.79% |
2023 Q4 | 65.31 Million CAD | 3.51% |
2022 FY | 69.88 Million CAD | 26.08% |
2022 Q4 | 69.88 Million CAD | 10.6% |
2022 Q3 | 63.18 Million CAD | 3.86% |
2022 Q2 | 60.84 Million CAD | 4.6% |
2022 Q1 | 58.16 Million CAD | 4.94% |
2021 Q2 | 55.31 Million CAD | -34.59% |
2021 Q4 | 55.42 Million CAD | 5.08% |
2021 Q3 | 52.74 Million CAD | -4.64% |
2021 FY | 55.42 Million CAD | 18.02% |
2021 Q1 | 84.56 Million CAD | 80.06% |
2020 Q1 | 48.64 Million CAD | 102.57% |
2020 Q4 | 46.96 Million CAD | -3.93% |
2020 Q2 | 49.84 Million CAD | 2.47% |
2020 Q3 | 48.88 Million CAD | -1.93% |
2020 FY | 46.96 Million CAD | 95.57% |
2019 FY | 24.01 Million CAD | 40182.48% |
2019 Q4 | 24.01 Million CAD | 1.0% |
2019 Q1 | 10.37 Million CAD | 17307.06% |
2019 Q3 | 23.77 Million CAD | 29.22% |
2019 Q2 | 18.4 Million CAD | 77.31% |
2018 FY | 59.61 Thousand CAD | -91.03% |
2018 Q4 | 59.61 Thousand CAD | 0.0% |
2018 Q1 | - CAD | -100.0% |
2018 Q3 | - CAD | 0.0% |
2017 Q4 | 19.26 Million CAD | 0.0% |
2017 FY | 664.67 Thousand CAD | -96.53% |
2016 FY | 19.16 Million CAD | 0.0% |
Name | Total Debt | Total Debt Difference |
---|---|---|
Newron Pharmaceuticals S.p.A. | 48.43 Million EUR | -49.736% |
Redcare Pharmacy NV | 275.49 Million EUR | 73.672% |